View of CRISPR/Cas9 Editing of the β-Globin Locus in Sickle Cell Disease and β-Thalassemia: Mechanistic Rationale, Clinical Evidence, and Future Directions

Return to Article Details CRISPR/Cas9 Editing of the β-Globin Locus in Sickle Cell Disease and β-Thalassemia: Mechanistic Rationale, Clinical Evidence, and Future Directions Download Download PDF